Biohaven’s Nurtec, with dual migraine approvals, hits $136M in quarterly sales and leads the pack in market share
Biohaven's migraine drug Nurtec ODT has been on a roll since becoming the first medicine to win a dual FDA approval to both treat and prevent migraines. Now, the comp...
Continue Reading →
